ALA 0.00% 12.0¢ arovella therapeutics limited

A new CEO/MD, page-3

  1. 362 Posts.
    lightbulb Created with Sketch. 278
    Don’t forget Phillips said at the AGM he was hoping to deliver a deal prior to the meeting so surely that has to be close now - could be anything...Zolpi Europe is long overdue?

    Only takes one deal of decent size with a reputable pharma to give validation to the Oromist IP and rerate the company significantly higher. Hopper outlined as much in his Chairman’s address, SUD’s EV is tiny - there is basically no value assigned by the market to the IP, backended royalty pipeline, Anagrelide upside, potential reformulation of any well consumed worldwide drug etc.

    Against a $10m market cap I still think this is still a decent play to be long on. Sure there will be more CRs but that shouldn’t be news to anyone...it will extend the runway further to position the company to finally realise that long dated royalty revenue and move to its focus of proving Anagrelide in-man via spray is effective.
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
(20min delay)
Last
12.0¢
Change
0.000(0.00%)
Mkt cap ! $126.0M
Open High Low Value Volume
12.0¢ 12.5¢ 12.0¢ $92.54K 764.8K

Buyers (Bids)

No. Vol. Price($)
10 376742 12.0¢
 

Sellers (Offers)

Price($) Vol. No.
12.5¢ 512180 6
View Market Depth
Last trade - 16.10pm 06/06/2024 (20 minute delay) ?
Last
12.3¢
  Change
0.000 ( 2.08 %)
Open High Low Volume
12.0¢ 12.5¢ 12.0¢ 296345
Last updated 15.43pm 06/06/2024 ?
ALA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.